Catalog No. |
TD-HV076016 |
Species reactivity |
Human |
Applications |
Research Grade Biosimilar |
Host species |
Human |
Isotype |
IgG1-lambda2 |
Expression system |
Mammalian Cells |
Clonality |
Monoclonal |
Target |
IL21R, NILR, Interleukin-21 receptor, IL-21R, IL-21 receptor, CD360, Novel interleukin receptor, Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279 |
Endotoxin level |
Please contact the lab for this information. |
Purity |
>95% purity as determined by SDS-PAGE. |
Purification |
Protein A/G, purified from cell culture supernatant. |
Accession |
Q9HBE5 & Q15116 |
Form |
Liquid |
Storage buffer |
0.01M PBS,pH7.4. |
Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
Alternate Names |
Bispecificantibody,AMG256,AMG-256,AMG256,CAS:2552814-07-8 |
Background |
Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research.Latikafusp may lead to the development of immunogenicity-mediated responses. |
Note |
For research use only. Not for use in clinical or therapeutic applications. |